Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study

Daniel B Horton, Emily S Barrett, Jason Roy, Maria Laura Gennaro, Tracy Andrews, Patricia Greenberg, Natalie Bruiners, Pratik Datta, Rahul Ukey, Senthil K Velusamy, Daniel Fine, William J Honnen, Yue Sandra Yin, Abraham Pinter, Andrew Brooks, Jay Tischfield, Sabiha Hussain, Sugeet Jagpal, Shobha Swaminathan, Veenat Parmar, Nancy Reilly, Sunanda Gaur, Reynold A Panettieri, Jeffrey L Carson, Martin J Blaser, Daniel B Horton, Emily S Barrett, Jason Roy, Maria Laura Gennaro, Tracy Andrews, Patricia Greenberg, Natalie Bruiners, Pratik Datta, Rahul Ukey, Senthil K Velusamy, Daniel Fine, William J Honnen, Yue Sandra Yin, Abraham Pinter, Andrew Brooks, Jay Tischfield, Sabiha Hussain, Sugeet Jagpal, Shobha Swaminathan, Veenat Parmar, Nancy Reilly, Sunanda Gaur, Reynold A Panettieri, Jeffrey L Carson, Martin J Blaser

Abstract

Background: We studied risk factors, antibodies, and symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a diverse, ambulatory population.

Methods: A prospective cohort (n = 831) previously undiagnosed with SARS-CoV-2 infection underwent serial testing (SARS-CoV-2 polymerase chain reaction, immunoglobulin G [IgG]) for 6 months.

Results: Ninety-three participants (11.2%) tested SARS-CoV-2-positive: 14 (15.1%) asymptomatic, 24 (25.8%) severely symptomatic. Healthcare workers (n = 548) were more likely to become infected (14.2% vs 5.3%; adjusted odds ratio, 2.1; 95% confidence interval, 1.4-3.3) and severely symptomatic (29.5% vs 6.7%). IgG antibodies were detected after 79% of asymptomatic infections, 89% with mild-moderate symptoms, and 96% with severe symptoms. IgG trajectories after asymptomatic infections (slow increases) differed from symptomatic infections (early peaks within 2 months). Most participants (92%) had persistent IgG responses (median 171 days). In multivariable models, IgG titers were positively associated with symptom severity, certain comorbidities, and hospital work. Dyspnea and neurologic changes (including altered smell/taste) lasted ≥ 120 days in ≥ 10% of affected participants. Prolonged symptoms (frequently more severe) corresponded to higher antibody levels.

Conclusions: In a prospective, ethnically diverse cohort, symptom severity correlated with the magnitude and trajectory of IgG production. Symptoms frequently persisted for many months after infection.Clinical Trials Registration. NCT04336215.

Keywords: COVID-19; SARS-CoV-2 infection; humoral immunity; longitudinal data analysis; postacute sequelae of COVID-19; prospective cohort; risk factors; symptoms.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Factors associated with SARS-CoV-2 infection. Forest plots show factors associated with infection in (A) Rutgers Corona Cohort participants (n = 831) and (B) the subset of healthcare workers (n = 548) as measured by positive SARS-CoV-2 PCR or antibody testing. Results reflect aORs from multivariable logistic regression models fitted with elastic net penalty for regularization and variable selection from among variables listed in Table 1. Reference groups included: age < 40 years (versus ≥ 60 years), white race (versus Asian race), and attending physician (vs nursing). Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; ICU, intensive care unit; OR, operating room; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 2.
Figure 2.
Average antibody levels over time among SARS-CoV-2–infected Rutgers Corona Cohort participants, stratified by symptom severity. Plots show estimated average levels of (A) total antibody and (B) IgG over time with 95% confidence intervals based on symptom severity. Curves and 95% confidence bands were estimated for different levels of symptom severity by fitting a model with a spline function for time and a random intercept to account for repeated measures. Abbreviations: Ig, immunoglobulin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 3.
Figure 3.
Factors associated with IgG titer among SARS-CoV-2–infected Rutgers Cohort participants (n = 81). Estimates reflect coefficients for factors in association with log-transformed IgG titer over time from a generalized additive mixed model, fitted with a spline for time. Factors reflect baseline values except disease severity (global assessment), cell counts (updated over time), and selected variables reflecting exposure in the first month of follow-up but excluding any values after SARS-CoV-2–positive testing (unprotected exposures to infected persons, worked on site). See “Methods” for details. Reference groups not shown are no symptoms, white race, and never smoker. Other chronic disease includes diabetes mellitus, cardio/cerebrovascular disease, cancer, chronic kidney disease, autoimmune disease, or immunosuppressant use. Chronic respiratory disease includes asthma, chronic obstructive pulmonary disease, or other chronic lung disease. Abbreviations: ALC, absolute lymphocyte count; ALT, alanine transaminase; ANC, absolute neutrophil count; CI, confidence interval; GFR, glomerular filtration rate; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 4.
Figure 4.
Duration of selected symptoms in infected RCC participants. Kaplan-Meier plots show prevalence and time course (in days) of 4 selected symptoms among infected RCC participants from infection to resolution: (A) fatigue; (B) loss of taste; (C) shortness of breath; and (D) neurologic changes besides altered taste or smell, eg, altered cognition or visual changes. Symptoms are shown in decreasing order of overall prevalence (AD). Median, 75th, and 90th percentiles are indicated for each symptom among those who reported the symptom. Abbreviations: %ile, percentile; RCC, Rutgers Corona Cohort.
Figure 5.
Figure 5.
Average antibody levels over time among SARS-CoV-2–infected Rutgers Corona Cohort participants, stratified by symptom duration. Plots show estimated average levels of IgG over time with 95% confidence intervals based on symptom duration. Curves and 95% confidence bands were estimated for different durations of symptoms by fitting a model with a spline function for time and a random intercept to account for repeated measures. Abbreviations: IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

References

    1. New York Times. Coronavirus map: tracking the global outbreak. . Accessed 18 December 2020.
    1. Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review. Ann Intern Med 2021; 174:655–62.
    1. Yanes-Lane M, Winters N, Fregonese F, et al. . Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis. PLoS One 2020; 15:e0241536.
    1. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. . Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med 2020; 17:e1003346.
    1. Li R, Pei S, Chen B, et al. . Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020; 368:489–93.
    1. Long QX, Tang XJ, Shi QL, et al. . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26:1200–4.
    1. Wajnberg A, Mansour M, Leven E, et al. . Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe 2020; 1:e283–9.
    1. Gudbjartsson DF, Norddahl GL, Melsted P, et al. . Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383:1724–34.
    1. Hansen CB, Jarlhelt I, Pérez-Alós L, et al. . SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals. J Immunol 2021; 206:109–17.
    1. Crawford KHD, Dingens AS, Eguia R, et al. . Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis 2021; 223:197–205.
    1. Patel MM, Thornburg NJ, Stubblefield WB, et al. . Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. JAMA 2020; 324:1781–2.
    1. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. . Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020; 383:1085–7.
    1. Wajnberg A, Amanat F, Firpo A, et al. . Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370:1227–30.
    1. Noh JY, Kwak JE, Yang JS, et al. . Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19. J Infect Dis 2021; 224:754–63.
    1. Trieu MC, Bansal A, Madsen A, et al. ; Bergen COVID-19 Research Group. SARS-CoV-2-specific neutralizing antibody responses in Norwegian health care workers after the first wave of COVID-19 pandemic: a prospective cohort study. J Infect Dis 2021; 223:589–99.
    1. New Jersey Department of Health. New Jersey COVID-19 dashboard. . Accessed 29 December 2020.
    1. Barrett ES, Horton DB, Roy J, et al. . Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers in New Jersey, at the onset of the U.S. COVID-19 pandemic. BMC Infect Dis 2020; 20:853.
    1. Radbel J, Jagpal S, Roy J, et al. . Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is comparable in clinical samples preserved in saline or viral transport medium. J Mol Diagn 2020; 22:871–5.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–81.
    1. Datta P, Ukey R, Bruiners N, et al. . Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection. medRxiv, doi: 10.1101/2021.07.09.21260266, 14. July 2021, preprint: not peer reviewed.
    1. Premkumar L, Segovia-Chumbez B, Jadi R, et al. . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 2020; 5:eabc8413.
    1. Barrett ES, Horton DB, Roy J, et al. . Risk factors for SARS-CoV-2 infection in hospital workers: results from a screening study in New Jersey, US in Spring 2020. Open Forum Infect Dis 2020; 7:ofaa534.
    1. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011; 30:377–99.
    1. Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med 2020; 173:120–36.
    1. Kambhampati AK, O’Halloran AC, Whitaker M, et al. . COVID-19–associated hospitalizations among health care personnel—COVID-NET, 13 states, March 1–May 31, 2020. Morb Mort Wkly Rep 2020; 69:1576.
    1. Shah ASV, Wood R, Gribben C, et al. . Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ 2020; 371:m3582.
    1. Grant JJ, Wilmore SMS, McCann NS, et al. . Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. Infect Control Hosp Epidemiol 2021; 42:212–4.
    1. Jacob JT, Baker JM, Fridkin SK, et al. . Risk factors associated with SARS-CoV-2 seropositivity among US health care personnel. JAMA Netw Open 2021; 4:e211283.
    1. Wang X, Ferro EG, Zhou G, Hashimoto D, Bhatt DL. Association between universal masking in a health care system and SARS-CoV-2 positivity among health care workers. JAMA 2020; 324:703–4.
    1. Rijkers G, Murk JL, Wintermans B, et al. . Differences in antibody kinetics and functionality between severe and mild severe acute respiratory syndrome coronavirus 2 infections. J Infect Dis 2020; 222:1265–9.
    1. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20:355–62.
    1. Robbiani DF, Gaebler C, Muecksch F, et al. . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020; 584:437–42.
    1. Long QX, Liu BZ, Deng HJ, et al. . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26:845–8.
    1. Lynch KL, Whitman JD, Lacanienta NP, et al. . Magnitude and kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity. Clin Infect Dis 2021; 72:301–8.
    1. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. . Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020; 183:158–68.e14.
    1. Chen Y, Zuiani A, Fischinger S, et al. . Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell 2020; 183:1496–507.e16.
    1. Alizon S, Haim-Boukobza S, Foulongne V, et al. . Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021. Euro Surveill 2021; 26:2100573.
    1. Centers for Disease Control and Prevention. COVID data tracker, variant proportions. . Accessed 30 July 2021.
    1. Liu C, Ginn HM, Dejnirattisai W, et al. . Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 2021; 184:4220–36.e13.
    1. Planas D, Veyer D, Baidaliuk A, et al. . Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021; 596:276–80.
    1. Nehme M, Braillard O, Alcoba G, et al. ; COVICARE TEAM. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med 2021; 174:723–5.
    1. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324: 603–5.
    1. Willi S, Lüthold R, Hunt A, et al. . COVID-19 sequelae in adults aged less than 50 years: a systematic review. Travel Med Infect Dis 2021; 40:101995.
    1. Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27:601–15.
    1. Gerhards C, Thiaucourt M, Kittel M, et al. . Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. Int J Infect Dis 2021; 107:221–7.

Source: PubMed

Подписаться